A young woman who developed angioedema of the small bowel after taking two different angiotensin-converting enzyme (ACE) inhibitors showed elevated D-dimer blood levels, according to a pair of researchers in China. Stopping the medication quickly eased her angioedema symptoms. Her D-dimer levels dropped to normal, too, leading researchers…
A man in Japan may have developed acquired angioedema as a late complication of graft-versus-host disease, which occurred when stem cells from a cord blood transplant he received to treat cancer turned against his own body, according to a recent report. A diagnosis was made based on a…
People with hereditary angioedema (HAE) who were new to Orladeyo (berotralstat) treatment saw rapid reductions in the number of swelling attacks they experienced soon after starting the oral therapy, according to real-world data from the U.S. The benefits of Orladeyo lasted as long as 18 months, or about…
Sebetralstat, an oral small molecule being developed by KalVista Pharmaceuticals as an on-demand treatment for hereditary angioedema (HAE), has been issued an innovation passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). An innovation passport is the first step into the U.K.’s Innovative Licensing and Access…
Three genetic regions were found to be associated with the risk of developing angioedema as a side effect of angiotensin-converting enzyme (ACE) inhibitors, according to a genome-wide association study (GWAS) of European and African-American people. These include a new genetic locus that hadn’t been…
People with hereditary angioedema (HAE) who switched from long-term androgen treatment to BioCryst Pharmaceuticals’ Orladeyo (berotralstat) saw a reduction in the number of swelling attacks. That’s according to a new analysis of data from patients who discontinued androgens less than 60 days (two months) before entering APeX-S…
Argentina’s regulatory body has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) to prevent swelling attacks in adults and adolescents, ages 12 and older, who have hereditary angioedema (HAE). The decision by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) comes a few months after the approval of…
Donidalorsen, an experimental treatment in the pipeline of Ionis Pharmaceuticals, continues to prevent swelling attacks when taken for up to two years, allowing a better quality of life for adults with hereditary angioedema (HAE). These results come from an ongoing open-label extension study (NCT04307381) in HAE…
Pharvaris is now gearing up startup activities with clinical site investigators and staff to launch a Phase 3 trial next year of PHVS416 — an immediate-release capsule formulation of deucrictibant — as an on-demand treatment for hereditary angioedema (HAE). The Switzerland-based clinical-stage company recently met with the U.S. Food…
A 58-year-old woman developed angioedema of the small bowel after three years of taking lisinopril, an angiotensin-converting enzyme (ACE) inhibitor often used for high blood pressure. The woman switched to amlodipine, a different blood pressure-lowering medication, and her signs and symptoms of angioedema resolved rapidly. Her case was…
Get regular updates to your inbox.
